September 24, 2021 10:56 AM EDT
News Briefing

Capri­cor's DMD clin­i­cal tri­al meets pri­ma­ry end­points; Delaware court rules against Take­da in Lupron feud

Paul Schloesser

Associate Editor

Bev­er­ly Hills, CA-based biotech Capri­cor Ther­a­peu­tics re­vealed to­day fi­nal da­ta from its clin­i­cal tri­al eval­u­at­ing stem cell ther­a­py CAP-1002 for pa­tients …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Ex­clu­sive: Day af­ter GSK buy­out, IDRx chair takes new in­vest­ing role at Curie.Bio

#JPM25 live blog day 2: Pfiz­er's po­lit­i­cal po­si­tion­ing; The newest bio­phar­mas to watch

Bio­haven’s pro­tein de­grad­er is promis­ing in ear­ly IgAN tri­al, heads straight to Phase 3

Dai­ichi Sankyo brings Gly­co­tope an­ti­body in-house for $132.5M

#JPM25 live blog day 1: How will Trump 2.0 im­pact the bio­phar­ma in­dus­try? Scott Got­tlieb, Bob Nelsen share ...

Up­dat­ed: J&J to buy In­tra-Cel­lu­lar for $14.6B in lat­est neu­ro­science bet

A service from the Financial Times